Altimmune (ALT) Financials: History & Chart

Altimmune, Inc.(ALT)

Biotechnology · Gaithersburg, MD

$2.66-0.01 (-0.37%)

Delayed quote: Oct 6, 2026, 10:10 AM EDT

About Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

Gaithersburg, MD

57 employees

altimmune.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jerome Benedict Durso

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	31K	0.00	0.00	26K	5K	5K	5K	5K	5K
Cost of Goods Sold	15.01M	23K	23K	0.00	14.96M	0.00	0.00	0.00	0.00
Gross Profit	-14.97M	-23K	-23K	26K	-14.96M	5K	5K	5K	5K
Gross Profit Margin	-48306.5%	N/A	N/A	100.0%	-299100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	85.27M	26.23M	24.22M	28.92M	5.90M	22.93M	21.82M	24.87M	24.77M
Research & Development	68.19M	18.66M	16.17M	18.41M	14.96M	17.24M	15.83M	19.78M	19.80M
Selling, General & Administrative	32.04M	7.57M	8.05M	10.51M	5.90M	5.69M	5.99M	5.09M	4.97M
Operating Income (EBIT)	-100.22M	-26.23M	-24.24M	-28.89M	-20.86M	-22.92M	-21.82M	-24.87M	-24.77M
Operating Margin	-323306.5%	N/A	N/A	-111126.9%	-417180.0%	-458440.0%	-436300.0%	-497320.0%	-495340.0%
Income Before Tax (EBT)	-91.76M	-22.82M	-22.56M	-27.36M	-19.01M	-22.15M	-20.26M	-23.18M	-22.84M
Interest Income	12.29M	4.53M	2.90M	2.44M	2.43M	1.13M	1.54M	1.57M	1.91M
Interest Expense	3.54M	1.10M	1.07M	876K	495K	264K	1K	1K	6K
Other Income/Expense	8.46M	3.40M	1.68M	1.53M	1.84M	776K	1.56M	1.69M	1.92M
Net Income	-91.76M	-22.82M	-22.56M	-27.36M	-19.01M	-22.15M	-19.57M	-23.18M	-22.84M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	-681K	0.00	0.00
Net Profit Margin	-296000.0%	N/A	N/A	-105223.1%	-380280.0%	-442920.0%	-391500.0%	-463600.0%	-456900.0%
EBITDA	-100.13M	-26.21M	-24.22M	-28.87M	-20.83M	-22.89M	-21.79M	-24.83M	-24.73M
EBITDA Margin	-322987.1%	N/A	N/A	-111026.9%	-416640.0%	-457840.0%	-435720.0%	-496660.0%	-494600.0%
Depreciation & Amortization	99K	23K	23K	26K	27K	30K	29K	33K	37K
EPS Basic	-0.78	-0.12	-0.18	-0.27	-0.21	-0.27	-0.26	-0.33	-0.32
EPS Diluted	-0.78	-0.12	-0.18	-0.27	-0.21	-0.27	-0.26	-0.33	-0.32
Weighted Average Basic Shares	185.44M	185.44M	124.46M	100.61M	89.42M	81.48M	75.55M	71.26M	71.08M
Weighted Average Diluted Shares	185.44M	185.44M	124.46M	100.61M	89.42M	81.48M	75.55M	71.26M	71.08M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	41K	20K	426K	-68K	4.41M	8.19M	5.80M	10.33M
Cost of Goods Sold	0.00	0.00	0.00	0.00	0.00	33.51M	0.00	18.46M
Gross Profit	41K	20K	426K	-68K	4.41M	-25.32M	5.80M	-8.13M
Gross Profit Margin	100.0%	100.0%	100.0%	100.0%	100.0%	-309.4%	100.0%	-78.7%
Total Operating Expenses	94.53M	103.19M	96.36M	87.67M	101.32M	29.47M	27.27M	28.22M
Research & Development	66.43M	82.23M	65.80M	70.54M	74.54M	49.77M	17.77M	18.46M
Selling, General & Administrative	28.10M	20.97M	18.14M	17.13M	15.41M	13.21M	8.50M	9.77M
Operating Income (EBIT)	-94.49M	-103.17M	-95.93M	-87.74M	-96.91M	-54.80M	-21.46M	-42.83M
Operating Margin	-230461.0%	-515860.0%	-22518.5%	129029.4%	-2197.6%	-669.5%	-370.0%	-414.6%
Income Before Tax (EBT)	-88.77M	-95.06M	-88.45M	-84.91M	-97.09M	-43.63M	-20.58M	-45.32M
Interest Income	7.54M	8.07M	7.35M	2.87M	203K	323K	843K	227K
Interest Expense	1.64M	9K	35K	8K	5K	9K	2K	297K
Other Income/Expense	5.71M	8.11M	7.48M	2.83M	-176K	11.17M	886K	-2.49M
Net Income	-88.09M	-95.06M	-88.45M	-84.71M	-97.09M	-49.04M	-20.52M	-39.17M
Income Tax Expense	-681K	0.00	0.00	-197K	0.00	5.42M	-59K	-6.15M
Net Profit Margin	-214861.0%	-475295.0%	-20762.2%	124577.9%	-2201.6%	-599.2%	-353.7%	-379.2%
EBITDA	-94.38M	-102.93M	-95.45M	-87.25M	-96.36M	-54.37M	-21.08M	-42.53M
EBITDA Margin	-230187.8%	-514670.0%	-22406.6%	128304.4%	-2185.1%	-664.3%	-363.3%	-411.7%
Depreciation & Amortization	112K	238K	477K	493K	551K	429K	387K	302K
EPS Basic	-1.00	-1.34	-1.66	-1.81	-2.35	-1.91	-1.56	-13.98
EPS Diluted	-1.00	-1.34	-1.66	-1.81	-2.35	-1.91	-1.56	-13.98
Weighted Average Basic Shares	88.10M	71.00M	53.25M	46.93M	41.28M	25.64M	13.12M	2.80M
Weighted Average Diluted Shares	88.10M	71.00M	53.25M	46.93M	41.28M	25.64M	13.12M	2.80M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.